Ascendis Pharma A/S (ASND) Expected to Release Earnings on Wednesday

Ascendis Pharma A/S (NASDAQ:ASND) is anticipated to issue its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of $0.8940 per share and revenue of $409.37 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.71 by ($0.68). The company had revenue of $387.22 million during the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. On average, analysts expect Ascendis Pharma A/S to post $3.43 EPS for the current fiscal year and $8.90 EPS for the next fiscal year.

Ascendis Pharma A/S Stock Up 0.5%

Shares of Ascendis Pharma A/S stock opened at $250.17 on Wednesday. The stock has a market capitalization of $15.61 billion, a P/E ratio of 19.41 and a beta of 0.40. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. The stock has a 50 day moving average price of $242.19 and a two-hundred day moving average price of $238.35. Ascendis Pharma A/S has a 12-month low of $188.07 and a 12-month high of $282.15.

Insider Activity at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean-Jacques Bienaimé purchased 2,000 shares of the company’s stock in a transaction on Friday, August 14th. The shares were bought at an average cost of $246.33 per share, with a total value of $492,660.00. Following the transaction, the director directly owned 2,900 shares in the company, valued at approximately $714,357. This represents a 222.22% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Mads Bodenhoff sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the transaction, the senior vice president owned 3,000 shares of the company’s stock, valued at approximately $810,570. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 40.00% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ASND. Bank of America reduced their price objective on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Raymond James Financial downgraded shares of Ascendis Pharma A/S from a “strong-buy” rating to an “outperform” rating and set a $287.00 price objective for the company. in a report on Tuesday, September 15th. UBS Group began coverage on shares of Ascendis Pharma A/S in a research note on Thursday, October 15th. They issued a “buy” rating and a $269.00 target price on the stock. Stifel Nicolaus dropped their target price on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating on the stock in a report on Monday, August 31st. Finally, Citigroup dropped their target price on shares of Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating on the stock in a report on Monday, October 26th. Nineteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $305.95.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve treatment convenience, maintain controlled drug exposure, and address unmet medical needs.

Its commercial products include SKYTROFA (lonape­gsomatropin-tcgd), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a once-daily therapy for adults with hypoparathyroidism.